It may be an understatement to say that the meta-analysis by Katsanos et al 1 published in December 2018 has sent a tidal wave through the vascular community, creating more confusion than offering answers for those who perform peripheral endovascular interventions. The results of pooled data from 28 randomized controlled trials (RCTs) of paclitaxel-eluting technologies [24 studies on drugcoated balloons (DCBs) and 4 on drug-eluting stents (DES)] used in 4663 patients showed that all-cause death at 2 years (reported in 12 RCTs) was significantly higher following the application of paclitaxel-coated devices [risk ratio (RR) 1.68, 95% confidence interval (CI) 1.15 to 2.47]. Similarly, all-cause death up to 5 years (reported in 3 studies: 1 with 4 years' and 2 with 5 years' follow-up) was significantly higher in the DCB/DES arm (pooled RR 1.93, 95% CI 1.27 to 2.93). Meta-regression analysis indicated a highly significant association between paclitaxel dose-time product and absolute risk of death.
These results are both surprising and alarming, as they suggest a paclitaxel-related excess mortality for patients with femoropopliteal (FP) disease and call into question the safety of paclitaxel-based therapies that have already been used in hundreds of thousands patients worldwide since their introduction into the peripheral endovascular arena over 10 years ago. It is noteworthy that since the introduction of peripheral paclitaxel-based therapies, the numbers of RCTs and registries on the use of paclitaxelcoated DCBs 2 and DES 3 in the FP region have accumulated to the point that they constitute the largest and strongest body of evidence on device performance ever produced for any peripheral endovascular therapy. Based on this volume of material, there was general agreement on the safety and efficacy of these devices until the publication of the Katsanos meta-analysis. 1 It is well accepted that DCBs/DES achieve better outcomes than plain balloon angioplasty in terms of long-term angiographic (patency rate, late lumen loss) and clinical results (target lesion revascularization and device-related events). 4, 5 Widespread and successful clinical use of these devices eventually culminated with recommendations from the European Society of Cardiology 2017 guidelines 6 on the management of peripheral vascular disease ("A" level evidence) and, more recently, the Society for Cardiovascular Angiography and Interventions 7 (Level 1-A evidence) for the use of DCBs as a first line endovascular treatment for a wide range of FP indications.
There are numerous arguments put forth [8] [9] [10] [11] [12] [13] [14] to counter the Katsanos meta-analysis 1 for those who simply do not believe or refuse to accept the results, for example, lack of standardization between trial endpoints preventing meaningful data comparison, lack of patient-level outcome, merging of DCB and DES device outcomes, lack of correlation between paclitaxel dose and mortality, and a paucity of longterm follow-up data for most of the included trials (100% at 12 months, 43% at 2 years, and only 10% at 4-5 years). Clearly these RCTs were never designed or powered to look at mortality outcomes in the first instance. Furthermore, there is currently no plausible mechanism of action related to paclitaxel that could be linked to delayed mortality, and no unexpected mortality distribution has been seen.
The biology of paclitaxel is well understood. It is used primarily as a chemotherapy agent at 200 to 400 times the concentration 15 compared to drug levels seen in FP treatment. It is virtually undetectable in blood plasma levels within a few hours of administration, so how this drug can be linked to deaths years in the future is a question that remains unanswered.
From a statistical viewpoint, the Katsanos meta-analysis 1 is well performed and robust, and we cannot ignore the findings of this landmark publication. A detrimental signal has been detected that we as a vascular community have to try and understand better. We should hope to tease out why this harmful association has been found for the sake of our patients. Three trials (BASIL-3 and SWEDEPAD I and II) using paclitaxel-based DCBs in at least one of their intervention arms have temporarily ceased recruitment until further clarification is found to explain this increased mortality signal.
The US Food and Drug Administration (FDA) published a provisional warning, in an albeit notably muted tone, in January 2019 on continuing DCB use. Two updates were issued in March and August, the latter after a public meeting of the Circulatory System Devices Panel. The results of the preliminary investigation acknowledged the safety issue raised by the meta-analysis. While the results of ongoing reviews based on patient-level data are awaited, the FDA recommended For many patients, alternative treatment options to paclitaxelcoated balloons and paclitaxel-eluting stents provide a more favorable benefit-risk profile based on currently available information. For individual patients judged to be at particularly high risk for restenosis and repeat femoropopliteal interventions, clinicians may determine that the benefits of using a paclitaxel-coated device outweigh the risk of late mortality. 16 As such, any decision to employ paclitaxel-eluting devices should be made only following full disclosure of all potential adverse outcomes to patients in whom their use is clearly indicated.
The UK Medicines and Healthcare products Regulatory Agency, the UK equivalent of the US FDA, has already put out a stronger statement on the issue. Their independent Paclitaxel Expert Advisory Group has recommended withholding the use of paclitaxel coated/eluting devices from routine clinical use in patients with intermittent claudication "as the potential mortality risk generally outweighs the benefits" but notes that the devices may still be used in patients with critical limb ischemia but with appropriate informed patient consent and an enhanced patient follow-up. 17 This may possibly be the first nail in the coffin for paclitaxel-coated balloons in the peripheral vasculature. It is not surprising that the cautionary warnings are coming from regulatory agencies whose sole aim is to safeguard patient welfare. They will generally err on the side of caution. Can any other technology take up the mantle if paclitaxel-coated platforms are consigned to the past?
Sirolimus, like paclitaxel, is a potent antiproliferative agent that prevents activation of smooth muscle cells after vascular injury. It places the cell, reversibly, into the G 0 resting phase (cytostatic), whereas paclitaxel acts late in the cell reproductive cycle, interfering with microtubule formation during cell division, leading to cell death (apoptosis). Unlike paclitaxel, sirolimus has beneficial, potent anti-inflammatory effects and a broader therapeutic range. In the coronary circulation, sirolimus-eluting stents have been shown to be safe and more effective than paclitaxel devices. Among cardiologists, sirolimus is perceived as superior to paclitaxel, mostly because of lower restenosis rates in the coronary bed following limuseluting vs paclitaxel-eluting DES. 18 However, until recently it has been difficult to package sirolimus onto a stentless balloon platform that can directly deliver it to the vessel wall in an adequate quantity to inhibit neointimal hyperplasia. Because of its poor bioavailability (ie, reduced drug uptake), it needs frequent top-ups compared to paclitaxel. Preclinical animal model testing using novel phospholipid-encapsulated sirolimus nanocarriers coated on balloon-only catheters demonstrated efficient transfer of sirolimus to all layers of the vessel wall, achieving high tissue concentration of drugs that persisted for days after application. 19 In the coronary literature, this work has been taken to the clinical arena. The Nanolute registry recently reported 12-month clinical outcomes of the novel sirolimus-coated balloon (SCB) called MagicTouch (Concept Medical Inc, Tampa, FL, USA) for the treatment of de novo coronary artery lesions and in-stent restenosis (ISR). 20 Sirolimus is encapsulated in nanocarriers and coated onto the hydrophilic surface of the balloon. There was a high procedural success rate (99.7%) with bailout stenting required in only 6.6% lesions. The overall device-orientated adverse cardiac events and target lesion revascularization (TLR) rates were low at 4.2% and 3.6%, respectively, at 1 year despite a high rate of diabetes (47%). Ali et al 18 recently reported the first direct comparison between paclitaxel-and sirolimus-coated balloons for the treatment of DES ISR in the coronary bed. They found that sirolimus was noninferior to paclitaxel in this setting, and the 2 devices provided equivalent 6-month angiographic performance.
Prior to the advent of nanotechnology, these advantages of sirolimus were difficult if not impossible to apply to the peripheral circulation, not only because of the greater quantity of drug that would naturally be required but also the above-mentioned balloon-coating difficulties. "Nude" sirolimus has slow tissue absorption, necessitating the use of a co-solvent to enhance tissue uptake. The sirolimus molecule also deactivates quickly when delivered into aqueous media, and first attempts to use the agent on DES in the superficial femoral artery (SFA) have shown marginal or no benefit.
The novel sirolimus-delivery technologies developed for coronary arteries have recently been tested in the periphery. The first-in-man XTOSI study of the MagicTouch SCB is an ongoing registry to investigate the safety and efficacy of this SCB in the treatment of both FP and below-the-knee (BTK) arterial lesions. 21 Interim results indicated that >90% of XTOSI trial patients had severe critical limb ischemia (Rutherford category 5 or 6); about 80% of patients had total occlusions in all their BTK arteries before angioplasty. Device and technical success were both 100%. Freedom from device-and procedure-related mortality was 100%. Limb salvage rate at 30 days was 97%. Freedom from clinically-driven TLR at 6 months was 91%. Primary patency at 6 months, independently and blindly assessed by duplex ultrasound, was 82%. There was no reported distal embolization or "slow flow phenomenon" after application of SCB in the BTK vessels. In a world's first, the MagicTouch SCB was recently granted "Breakthrough Device Designation" by the US FDA for the treatment of BTK disease (www.conceptmedical.com).
In the Selution trial, 50 patients with complex SFA disease (30% total occlusions, 34% moderately severe or severe calcification, lumen loss 6.4 cm) were treated with a novel SCB that utilizes micro-reservoirs and a transfer membrane. 22 This technology increases drug uptake into the artery wall, prolongs exposure to the drug, reduces dose loss to circulation, and minimizes embolization. Combined with the wide safety margin of sirolimus compared to paclitaxel, these features allow a low dose of drug on the balloon, thus facilitating the use of large and multiple balloons during intervention. The device was found to be safe; the median late lumen loss at 6 months was 0.19 mm, and the TLR rate was 2.3%, 23 outcomes at least as good as paclitaxel DCBs. The device is approaching commercialization in Europe, and plans are underway to begin an investigational drug evaluation trial in the United States.
SCBs may offer a new approach to the treatment of peripheral vascular disease. However, future studies using the technology will need to address the shortcomings of the paclitaxel-based clinical trials. For example, patients will need to be followed more closely and for a longer period of time. There remains the possibility that not all patients enrolled in the paclitaxel-based trials were followed the same way, potentially resulting in surveillance bias in previously reported outcomes. For example, did patients with better outcomes require less scrutiny and thus had suboptimal medical management and subsequently higher mortality? We would recommend all patients be enrolled into a mandatory registry to collect outcome data for at least 5 years.
Another important question that future studies of any drug-eluting technology for the periphery will need to address is the effect of the drug in terms of late lumen enlargement. Paclitaxel has shown this characteristic because of its effect on the extracellular matrix level, which renders this drug particularly appealing for native vessel and restenotic disease, 24 but which can also lead to aneurysm formation in rare cases. 25 To address this question, sirolimus will need to effectively reach the tunica adventitia to induce vessel wall remodeling while not inducing overexpansion of the treated lumen.
